The World Health Organization, the United Nations Children’s Fund, the International Federation of Red Cross and Red Crescent Societies and Médecins Sans Frontières jointly announced on January 11 local time that they would establish a global Ebola vaccine reserve.
In the future, once the epidemic breaks out again, vaccines can be quickly mobilized and immunized high-risk populations.
Seed, thus stopping the spread of the virus.
The first batch of vaccines entering the inventory totaled 6,890, and it is expected to complete the reserve level of 500,000 in two to three years.
The reserve is located in Switzerland and is managed by UNICEF on a daily basis, and the related funds are provided by the Global Alliance for Vaccines and Immunization.
The vaccine was developed and produced by Mercadon Group as a single injection vaccine.
It has been licensed by the European Drug Administration, the United States Food and Drug Administration and eight African governments, and has passed the WHO drug pre-qualification.
Previously, the vaccine had been used urgently during the Ebola epidemic in Guinea and the Democratic Republic of the Congo, with more than 350,000 people vaccinated.
